©2024 Stanford Medicine
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Not Recruiting
Trial ID: NCT00435916
Purpose
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective
response rate and assess toxicity in patients with relapsed DLBCL.
Official Title
A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Diagnosis of DLBCL.
- Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP,
R-ESHAP or equivalent.
- Progression or relapse since most recent therapy.
- At least one measurable lesion that is both greater than or equal to 2 cm by
conventional CT or greater than or equal to 1.5 cm by spiral CT.
Exclusion Criteria:
- Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or
central nervous system lymphoma.
- Primary refractory disease.
- Received an allogenic stem cell transplant.
Intervention(s):
drug: SGN-40
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ranjana Advani
6507248372